Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other 1Lymphoid 1Head & Neck 1

Conditions

Mucositis 1Head and Neck Neoplasms 1Abnormalities, Radiation-Induced 1

Interventions

naloxegol 5Metformin 4alvimopan 3Radiotherapy 3tegaserod 2Testosterone Propionate 2Surveys and Questionnaires 2Standard of Care 2Liraglutide 2Glutamine 2Fibroblast Growth Factor 7 2Exenatide 2Early Intervention, Educational 2semaglutide 1prucalopride 1oxycodone-acetaminophen 1oxycodone naloxone combination 1lime 1dapagliflozin 1cyclohexaneacetic acid 1bicalutamide 1acetaminophen, hydrocodone drug combination 1Testosterone 1Taxes 1Tamoxifen 1Tadalafil 1Sugars 1Sugammadex 1Sucralfate 1Sodium-Glucose Transporter 2 Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × oxycodone-acetaminophen × Other × Clear all
NCT02480114 2021-02-18

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Vanderbilt-Ingram Cancer Center

Phase 3 Completed
79 enrolled 8 charts
Head & NeckOther

Abnormalities, Radiation-Induced, Head and Neck Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡